Updates are available Correction dated 2023-09-04

Article History

Received: 20 February 2023

Accepted: 18 March 2023

First Online: 28 March 2023

Change Date: 4 September 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00702-023-02690-x

Declarations

:

: V. S. received compensation for consulting services and/or speaking activities from AveXis, Cytokinetics, Italfarmaco, Liquidweb S.r.l., Novartis Pharma AG and Zambon, receives or has received research supports from the Italian Ministry of Health, AriSLA, and E-Rare Joint Transnational Call. He is in the Editorial Board of <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i>, <i>European Neurology</i>, <i>American Journal of Neurodegenerative Diseases</i>, <i>Frontiers in Neurology</i> and <i>Exploration of Neuroprotective Therapy</i>. B.P. received compensation for consulting services and/or speaking activities from Liquidweb S.r.l B.P is Associated Editor for <i>Frontiers in Neuroscience</i>. N. T. received compensation for consulting services from Amylyx Pharmaceuticals and Zambon Biotech SA. He is Associate Editor for <i>Frontiers in Aging Neuroscience</i>.

: This study was approved by the Ethics Committees of IRCCS Istituto Auxologico Italiano (I.D.: 23C923_2019) and University of Campania “Luigi Vanvitelli”.

: Participants provided informed consent.